Table 1. Summary of clinicopathologic and cytogenetic findings of 32 myeloid neoplasms with isolated i(17q) cytogenetic abnormality.
| Variable | MDS/MPN (n = 13, 41%) | AML (n = 17, 53%) | MDS (n = 1, 3%) | MPN (n = 1, 3%) |
|---|---|---|---|---|
| Median age (range) | 64 years (51–83) | 66 years (24–78) | 55 years | 60 years |
| Gender (female/male) | 9/4 | 8/9 | 0/1 | 0/1 |
| Hemoglobin* (g/dL) | 9.4 (6.8–12.1) | 10.1 (6.4–12.8) | 8.6 | 12.9 |
| MCV | 88 (78–102) | 88 (70–110) | 91.5 | 104 |
| Absolute neutrophil count*, × 109/L | 3.6 (0.5–122.2) | 3.0 (0–24.2) | 1.9 | 5.7 |
| Platelet count*, × 109/L | 54 (10–143) | 57 (15–271) | 92 | 141 |
| Peripheral blood blasts* (%) | 1 (0–13) | 26 (0–97) | 0 | 1 |
| Bone marrow blasts* (%) | 8 (2–19) | 37 (7–93) | 12 | 0 |
| Cytogenetic evolution, n (%) | 30.8% | 23.5% | ||
| Without clonal evolution | 9 | 13 | 0 | 1 |
| With clonal evolution | 4 | 4 | 1 | 0 |
| Survival | 12 died, 1 lost to follow-up | 14 died, 1 alive, 2 lost to follow-up | Died | Died |
| 2008 WHO sub-classification | CMML (n = 6) MDS/MPN-U (n = 5) aCML (n = 2) | De novo/AML MRC (n = 9); sAML: h/o myeloid neoplasm (n = 5) and therapy-related (n = 2); AML, relapsed post-allogeneic SCT, unclassifiable (n = 1) | RAEB-2 | Post-ET MF |
aCML, atypical chronic myeloid leukemia; AML, acute myeloid leukemia; AML MRC, AML with myelodysplasia-related changes; CMML, chronic myelomonocytic leukemia; MCV, mean corpuscular volume; MDS, myelodysplastic syndrome; MDS/MPN-U, myelodysplastic/myeloproliferative neoplasm unclassifiable; Post-Et MF, Post-essential thrombocythemia myelofibrosis; RAEB, refractory anemia with excess blasts; sAML, secondary AML; SCT, stem cell transplant.